Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Millennium: The Takeda Oncology Company
In Clinical Trials VELCADE® Bortezomib for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients
June 16th, 2009
Millennium: The Takeda Oncology Company reported the presentation of results from two clinical trials of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). An overall response rate (ORR) of 84 percent was observed in one study of VELCADE, cyclophosphamide and dexamethasone (VcCD) as induction therapy, and an ORR of 97 percent was observed in a study of VELCADE, lenalidomide, doxorubicin and dexamethasone (VcRDD). These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Florida, May 29 – June 2, 2009. “These presentations validate that researchers are attempting to...
Source: Cancer Weekly (2009-06-16)
|
